MeiraGTx receives $50M milestone from Janssen for bota-vec Phase 3 extension study

MeiraGTx Holdings plc

$50M milestone triggered by initiation of LUMEOS extension study for bota-vec (XLRP gene therapy).
Additional $15M in near-term milestone payments expected later in 2024 from Janssen.
Up to $285M further payments on first U.S./EU commercial sales and manufacturing tech transfer.
Commercial supply agreement with J&J for bota-vec manufacturing expected to generate ongoing revenue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.